On Demand

In your opinion, what are the key treatment goals in second-line mRCC?

Michele Milella

In this video, Dr. Michele Milella talks about his opinion on key treatment goals in second-line mRCC.

On Demand

Would continued VEGF inhibition after progression on a VEGFR-targeted agent in the first line make biological sense

Michele Milella

In this video, Dr. Michele Milella talks about whether continued VEGF inhibition after progression on a VEGFR-targeted agent in first-line makes biological sense.

On Demand

In the absence of validated predictive markers, what clinical considerations would influence therapeutic choices?

Michele Milella

In this video, Dr. Michele Milella talks about which clinical considerations would influence his therapeutic choices, in the absence of validated predictive markers.

On Demand

Is there an impact on tumour burden and sites of metastases on treatment decisions in second line?

Michele Milella

In this video, Dr. Michele Milella talks about the potential impact of tumour burden and metastatic sites on treatment decisions in the second-line mRCC management.

On Demand

How do you personally decide between staying on VEGF inhibition or moving to an IO agent?

Michele Milella

In this video, Dr. Michele Milella talks about his (personal) algorithm for the selection of treatment in the second-line setting, deciding whether to continue VEGF inhibition or change to immunotherapy.

On Demand

If not you, then who?

Dr. Roger Henderson - Senior GP, Shropshire

Ever wondered how you can discuss smoking cessation in a COPD consultation? Or what does a brief consultation on smoking cessation look like?  These webinars bring solutions to these two challenges, to life.

On Demand

PALOMA-1 trial

Pfizer

This 3 minute animation video which provides an overview of the PALOMA-1 trial consisting of information such as study design, efficacy and quality of life (QoL). Once you have viewed the video and if you require further information please select the relevant tabs. 

On Demand

IBRANCE® (palbociclib) Oligometastases

Dr. John Connibear

In this video Dr. Connibear provides his professional opinion on the following topics:

  • Definition of oligometastatic disease
  • What challenges do oligometastases present in breast cancer?
  • How do you decide treatment for patients with metastatic breast cancer?
  • How might we drive better outcomes in oligometastatic breast cancer?
On Demand

IBRANCE® (palbociclib) locally advanced breast cancer

Dr. Henry Cain

In this video Henry Cain provides his professional opinion on the following topics:

  • What is locally advanced inoperable breast cancer?
  • What is the significance of the MDT, and of the patient’s opinion and quality of life when deciding therapy?
  • What could CDK4/6 inhibitors, such as Ibrance mean for patients with ER+, HER2- locally advanced disease?
On Demand

Implementing smoking cessation in hospitals

Matthew Evison - Consultant in Respiratory Medicine, Greater Manchester

Gareth Jones - Consultant Respiratory Physician, Royal Liverpool University Hospital

Hosted by Noel Baxter, GP and clinical commissioner for NHS Southwark and chair elect for the Primary Care Respiratory Society UK (PCRS-UK).